{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:40:37Z","timestamp":1789231237731,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11883-022-01019-5","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T01:02:21Z","timestamp":1649293341000},"page":"427-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8119-1245","authenticated-orcid":false,"given":"Rodrigo","family":"Alonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Arg\u00fceso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"\u00c1lvarez-Ba\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidio","family":"Mu\u00f1iz-Grijalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Diaz-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"1019_CR1","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41569-019-0325-8","volume":"17","author":"GF Watts","year":"2020","unstructured":"\u2022 Watts GF, Gidding S, Mata P, Pang J, Sullivan DR, Yamashita S, et al. Familial hypercholesterolemia: evolving knowledge for designing adaptive models of care. Nat Rev Cardiol. 2020;17:360\u201377. (This publication summarizes recent advances in the knowledge of FH related to diagnosis, cardiovascular risk stratification, LDL-C targets, and management.)","journal-title":"Nat Rev Cardiol"},{"key":"1019_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0021-9150(99)00336-6","volume":"149","author":"EJ Sijbrands","year":"2000","unstructured":"Sijbrands EJ, Westendorp RG, Lombardi MP, Havekes LM, Frants RR, Kastelein JJ, et al. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolemia. Atherosclerosis. 2000;149:421\u20135.","journal-title":"Atherosclerosis"},{"key":"1019_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.atherosclerosis.2007.12.024","volume":"200","author":"R Alonso","year":"2008","unstructured":"Alonso R, Mata N, Castillo S, Fuentes F, Saenz P, Mu\u00f1iz O, et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis. 2008;200:315\u201322.","journal-title":"Atherosclerosis"},{"key":"1019_CR4","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","volume":"37","author":"M Benn","year":"2016","unstructured":"Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolemia: screening of 98098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J. 2016;37:1384\u201394.","journal-title":"Eur Heart J"},{"key":"1019_CR5","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1161\/ATVBAHA.116.307514","volume":"36","author":"L Perez de Isla","year":"2016","unstructured":"Perez de Isla L, Alonso R, Mata N, Saltijeral A, Mu\u00f1iz O, Rubio-Marin P, et al. Coronary heart disease peripheral arterial disease, and stroke in familial hypercholesterolemia Insights from the SAFEHEART Registry. Arterioscler Thromb Vasc Biol. 2016;36:2004\u201310.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1019_CR6","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF, et al. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844\u20135853.","journal-title":"Eur Heart J"},{"key":"1019_CR7","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","volume":"63","author":"R Alonso","year":"2014","unstructured":"Alonso R, Andres E, Mata N, Fuentes-Jim\u00e9nez F, Badim\u00f3n L, L\u00f3pez-Miranda J, et al. SAFEHEART Investigators. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014;63:1982\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1019_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/joim.12335","volume":"278","author":"R Vongpromek","year":"2015","unstructured":"Vongpromek R, Bos S, Ten Kate GJ, Yahya R, Verhoeven AJ, de Feyter PJ, et al. Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia. J Intern Med. 2015;278:166\u201373.","journal-title":"J Intern Med"},{"key":"1019_CR9","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1093\/eurheartj\/ehaa1066","volume":"42","author":"L Perez de Isla","year":"2021","unstructured":"\u2022\u2022 Perez de Isla L, Watts GF, Alonso R, D\u00edaz-D\u00edaz JL, Mu\u00f1iz-Grijalvo O, Zamb\u00f3n D, et al. Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolemia. Eur Heart J. 2021;42:2201\u201311. (This study shows that aortic valve replacement due to AV stenosis is significantly increased in FH, and predictors are older age, history of ASCVD, hypertension, high lipoprotein(a) levels, and LDL-C adjusted Lp(a) burden.\u2022\u2022)","journal-title":"Eur Heart J"},{"key":"1019_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","volume":"4","author":"A Langsted","year":"2016","unstructured":"Langsted A, Kamstrup P, Benn M, Tybjaerg-Hansen A, Nordestgaard B. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolemia: a prospective cohort study. Lancet Diabetes Endocrinol. 2016;4:577\u201387.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1019_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano A, Koskinas KC, Casula M, Badim\u00f3n L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"1019_CR12","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/S0140-6736(69)90930-1","volume":"II","author":"J Slack","year":"1969","unstructured":"Slack J. Risks of ischaemic heart disease in familial hyperlipidemic states. Lancet. 1969;II:1380\u20132.","journal-title":"Lancet"},{"key":"1019_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0002-9149(00)01429-6","volume":"87","author":"P Hopkins","year":"2001","unstructured":"Hopkins P, Stephenson S, Wu L, Riley WA, Xin Y, Hunt SC. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2001;87:547\u201353.","journal-title":"Am J Cardiol"},{"key":"1019_CR14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","volume":"303","author":"Scientific Steering Committee on behalf of the Simon Broome Register Group","year":"1991","unstructured":"Scientific Steering Committee on behalf of the Simon Broome Register Group. The risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ. 1991;303:893\u20136.","journal-title":"BMJ"},{"key":"1019_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2019.08.007","volume":"289","author":"PB Duell","year":"2019","unstructured":"Duell PB, Gidding S, Andersen R, Knickelbine T, Anderson L, Gianos E, et al. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: the CASCADE FH registry. Atherosclerosis. 2019;289:85\u201393.","journal-title":"Atherosclerosis"},{"key":"1019_CR16","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","volume":"67","author":"A Khera","year":"2016","unstructured":"Khera A, Won HH, Peloso G, Lawson KS, Bartz TM, Deng X, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016;67:2578\u201389.","journal-title":"J Am Coll Cardiol"},{"key":"1019_CR17","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","volume":"29","author":"A Neil","year":"2008","unstructured":"Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;29:2625\u201333.","journal-title":"Eur Heart J"},{"key":"1019_CR18","doi-asserted-by":"publisher","first-page":"a2423","DOI":"10.1136\/bmj.a2423","volume":"337","author":"J Versmissen","year":"2008","unstructured":"Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.","journal-title":"BMJ"},{"key":"1019_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1172\/JCI115855","volume":"90","author":"E Boerwinkle","year":"1992","unstructured":"Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52\u201360.","journal-title":"J Clin Invest"},{"key":"1019_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0021-9150(81)90103-9","volume":"38","author":"GM Kostner","year":"1981","unstructured":"Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981;38:51\u201361.","journal-title":"Atherosclerosis"},{"key":"1019_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A test in context: lipoprotein(a). Diagnosis, prognosis, controversies and emerging therapies. J Am Coll Cardiol. 2017;69:692\u2013711.","journal-title":"J Am Coll Cardiol"},{"key":"1019_CR22","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1073\/pnas.86.11.4171","volume":"86","author":"G Utermann","year":"1989","unstructured":"Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E. Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci USA. 1989;86:4171\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1019_CR23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1161\/01.ATV.20.2.522","volume":"20","author":"HG Kraft","year":"2000","unstructured":"Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arteriosclerr Thromb Vasc Biol. 2000;20:522\u20138.","journal-title":"Arteriosclerr Thromb Vasc Biol"},{"key":"1019_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2017.03.021","volume":"260","author":"S Li","year":"2017","unstructured":"Li S, Wu NQ, Zhu CG, Zhang Y, Guo YL, Gao Y, et al. Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease. Atherosclerosis. 2017;260:67\u201374.","journal-title":"Atherosclerosis"},{"key":"1019_CR25","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1016\/j.jacc.2020.03.065","volume":"75","author":"M Trinder","year":"2020","unstructured":"Trinder M, DeCastro M, Azizi H, Cermakova L, Jackson LM, Frohlich J, et al. Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia. J Am Coll Cardiol. 2020;75:2682\u201393.","journal-title":"J Am Coll Cardiol"},{"key":"1019_CR26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","volume":"73","author":"K Ellis","year":"2019","unstructured":"\u2022\u2022 Ellis K, Perez de Isla L, Alonso R, Fuentes F, Watts G, Mata P. Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia. J Am Coll Cardiol. 2019;73:1029\u201339 (This study shows the feasibility and effectiveness of testing Lp(a) levels during FH cascade screening. Those FH patients with FH and high Lp. (This study shows the feasibility and effectiveness of testing Lp(a) levels during FH cascade screening. Those FH patients with FH and high Lp(a) levels have the highest risk of ASCVD compared to each disorder separately.\u2022\u2022)","journal-title":"J Am Coll Cardiol"},{"key":"1019_CR27","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.cca.2011.05.036","volume":"412","author":"K Kinpara","year":"2011","unstructured":"Kinpara K, Okada H, Yoneyama A, Okubo M, Murase T. Lipoprotein(a)-cholesterol: a significant component of serum cholesterol. Clin Chim Acta. 2011;412:1783\u20137.","journal-title":"Clin Chim Acta"},{"key":"1019_CR28","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.clinbiochem.2014.04.023","volume":"47","author":"R Saeedi","year":"2014","unstructured":"Saeedi R, Li M, Allard M, Frohlich J. Marked effects of extreme levels of lipoprotein(a) on estimation of low-density lipoprotein cholesterol. Clin Biochem. 2014;47:1098\u20139.","journal-title":"Clin Biochem"},{"issue":"6","key":"1019_CR29","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","volume":"256","author":"AC Jansen","year":"2004","unstructured":"Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004;256(6):482\u201390.","journal-title":"J Intern Med"},{"key":"1019_CR30","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.atherosclerosis.2011.02.007","volume":"216","author":"M Nenseter","year":"2011","unstructured":"Nenseter M, Lindvig HW, Ueland T, Langslet G, Ose L, Holven KB, et al. Lipoprotein(a) levels in coronary heart disease-susceptible and-resistant patients with familial hypercholesterolemia. Atherosclerosis. 2011;216:426\u201332.","journal-title":"Atherosclerosis"},{"key":"1019_CR31","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.5114\/amsad.2020.97105","volume":"5","author":"J Watanabe","year":"2020","unstructured":"Watanabe J, Hamasaki M, Kotani K. Risk of cardiovascular disease with lipoprotein(a) in familial hypercholesterolemia: a review. Arch Med Sci Atheroscler Dis. 2020;5:e148\u201352.","journal-title":"Arch Med Sci Atheroscler Dis"},{"key":"1019_CR32","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","volume":"135","author":"L P\u00e9rez de Isla","year":"2017","unstructured":"P\u00e9rez de Isla L, Alonso R, Mata N, Fern\u00e1ndez-P\u00e9rez C, Mu\u00f1iz O, D\u00edaz-D\u00edaz JL, et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017;135:2133\u201344.","journal-title":"Circulation"},{"key":"1019_CR33","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1161\/ATVBAHA.121.316106","volume":"41","author":"M Paquette","year":"2021","unstructured":"Paquette M, Bernard S, Cariou B, Hegele RA, Genest J, Trinder M, et al. Familial hypercholesterolemia-risk-score: a new score predicting cardiovascular events and cardiovascular mortality in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2021;41:2632\u201340.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1019_CR34","doi-asserted-by":"publisher","first-page":"zwab185","DOI":"10.1093\/eurjpc\/zwab185","volume":"2","author":"L P\u00e9rez de Isla","year":"2021","unstructured":"P\u00e9rez de Isla L, Watts GF, Mu\u00f1iz-Grijalvo O, D\u00edaz-D\u00edaz JL, Alonso R, Zamb\u00f3n D, et al. A resilient type of familial hypercholesterolemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort. Eur J Prev Cardiol. 2021;2:zwab185. https:\/\/doi.org\/10.1093\/eurjpc\/zwab185.","journal-title":"Eur J Prev Cardiol"},{"issue":"21","key":"1019_CR35","doi-asserted-by":"publisher","first-page":"01417","DOI":"10.1016\/j.atherosclerosis.2021.11.004","volume":"S0021\u20139150","author":"A Chakraborty","year":"2021","unstructured":"Chakraborty A, Pang J, Chan D, Ellis K, Hooper AJ, Bell DA, et al. Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolemia and elevated lipoprotein(a). Atherosclerosis. 2021;S0021\u20139150(21):01417\u20139. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.11.004.","journal-title":"Atherosclerosis"},{"issue":"3","key":"1019_CR36","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0735-1097(96)00563-3","volume":"29","author":"BF Stewart","year":"1997","unstructured":"Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, et al. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol. 1997;29(3):630\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"1019_CR37","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","volume":"359","author":"AB Rossebo","year":"2008","unstructured":"Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Investigators SEAS. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343\u201356.","journal-title":"N Engl J Med"},{"key":"1019_CR38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","volume":"121","author":"KL Chan","year":"2010","unstructured":"Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306\u201314.","journal-title":"Circulation"},{"key":"1019_CR39","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1001\/jama.2014.13959","volume":"312","author":"JG Smith","year":"2014","unstructured":"Smith JG, Luk K, Schulz CA, Engert JC, Do R, Hindy G, et al. Association of low-density lipoprotein-cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA. 2014;312:1764\u201371.","journal-title":"JAMA"},{"key":"1019_CR40","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1109034","volume":"368","author":"G Thanassoulis","year":"2013","unstructured":"Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503\u201312.","journal-title":"N Engl J Med"},{"key":"1019_CR41","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","volume":"66","author":"R Capoulade","year":"2015","unstructured":"Capoulade R, Chan KL, Yeang C, Mathieu P, Boss\u00e9 Y, Dumesnil JG, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol. 2015;66:1236\u201346.","journal-title":"J Am Coll Cardiol"},{"key":"1019_CR42","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/MOL.0000000000000794","volume":"32","author":"P Mata","year":"2021","unstructured":"Mata P, Alonso R, Perez de Isla L, Badim\u00f3n L. Dyslipidemia and aortic valve disease. Curr Opin Lipidol. 2021;32:349\u201354.","journal-title":"Curr Opin Lipidol"},{"key":"1019_CR43","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jacl.2016.04.006","volume":"10","author":"R Alonso","year":"2016","unstructured":"Alonso R, D\u00edaz-D\u00edaz JL, Arrieta F, Fuentes-Jim\u00e9nez F, de Andr\u00e9s R, Saenz P, et al. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: insights from SAFEHEART registry. J Clin Lipidol. 2016;10:953\u201361.","journal-title":"J Clin Lipidol"},{"key":"1019_CR44","first-page":"2508","volume":"40","author":"AC Alves","year":"2020","unstructured":"Alves AC, Alonso R, D\u00edaz-D\u00edaz JL, Medeiros AM, Jannes CE, Merchan A, et al. Phenotypical, clinical, and molecular aspects of adults and children with homozygous familial hypercholesterolemia in Iberoamerica. Arterioscler Thromb Vasc Biol. 2020;40:2508\u201315.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1019_CR45","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1016\/j.jacc.2015.09.087","volume":"66","author":"GR Ten Kate","year":"2015","unstructured":"Ten Kate GR, Bos S, Dedic A, Neefjes LA, Kurata A, Langendonk JG, et al. Increased aortic valve calcification in familial hypercholesterolemia: prevalence, extent, and associated risk factors. J Am Coll Cardiol. 2015;66:2687\u201395.","journal-title":"J Am Coll Cardiol"},{"key":"1019_CR46","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/jamacardio.2019.3903","volume":"4","author":"LJ Mundal","year":"2019","unstructured":"Mundal LJ, Hovland A, Igland J, Veierod MB, Holven KB, Bogsrud MP, et al. Association of low-density lipoprotein cholesterol with risk of aortic valve stenosis in familial hypercholesterolemia. JAMA Cardiol. 2019;4:1156\u20139.","journal-title":"JAMA Cardiol"},{"key":"1019_CR47","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.recesp.2019.10.013","volume":"73","author":"L Perez de Isla","year":"2020","unstructured":"Perez de Isla L, Arroyo-Olivares R, Alonso R, Mu\u00f1iz-Grijalvo O, D\u00edaz-D\u00edaz JL, Zamb\u00f3n D, et al. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry. Rev Esp Cardiol. 2020;73:828\u201334.","journal-title":"Rev Esp Cardiol"},{"key":"1019_CR48","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jacl.2021.04.011","volume":"15","author":"R Alonso","year":"2021","unstructured":"Alonso R, Mu\u00f1iz-Grijalvo O, D\u00edaz-D\u00edaz JL, Zamb\u00f3n D, de Andr\u00e9s R, Arroyo-Olivares R, et al. Efficacy of PCSK9 inhibitor in the treatment of heterozygous familial hypercholesterolemia: a clinical practice experience. J Clin Lipidol. 2021;15:584\u201392.","journal-title":"J Clin Lipidol"},{"key":"1019_CR49","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"\u2022\u2022 Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244\u201355. (This RCS shows a dose-dependent reduction in Lp(a) levels ranging 35 to 80% using weekly subcutaneous infection of antisense oligonucleotide AKCEA-APO(a)-LRX. The most common adverse event was injection-site reactions.\u2022\u2022)","journal-title":"N Engl J Med"},{"key":"1019_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2019.10.010","volume":"291","author":"YX Cao","year":"2019","unstructured":"Cao YX, Jin JL, Guo YL, Sun D, Liu HH, Wu NQ, et al. Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia. Atherosclerosis. 2019;291:27\u201333.","journal-title":"Atherosclerosis"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-01019-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-022-01019-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-01019-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T18:14:15Z","timestamp":1654193655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-022-01019-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1019"],"URL":"https:\/\/doi.org\/10.1007\/s11883-022-01019-5","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"assertion":[{"value":"9 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent."}},{"value":"Dr. Alonso reports personal fees from Tecnofarma and Teva, outside the submitted work.The other authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}